I agree that it is too easy to just chalk this up to inexperience.
I doubt many small biotech companies would have experience in the situation that is currently in front of NWBO. I similarly doubt that many BP's would be experienced in this situation as well. I think the difference is that BP have so many more resources and staff that they will not have to face some of the delays that NWBO is currently facing due to lack of staffing/resources.
I also agree that it is amazing how little the pandemic is included in the talks here.
Thermoo is right in his assessment that they are taking their time for the good of the long term prospects and making sure they get it right. That is the general idea I have gotten from my personal conversations and conversations posted on this board with DI. I think of all the interpretations of these conversations, it is what DI wants people to know is their number one priority.
I have seen people here equating lack of experience with lack of competence, which is, in my opinion, as far from the truth as possible.